Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Potential for Actiphage to provide ‘test of cure’ for new TB drugs

Accurate and rapid drug resistance testing is essential for early diagnosis of both drug-sensitive and drug-resistant TB.
  • April 13, 2023
  • HUMAN TB, Latest, Press release
Actiphage offers the potential for a ‘test of cure’ for TB drug treatment

Tuberculosis is on the rise and increasing resistance to the two most potent first-line TB drugs – Isoniazid and Rifampin – is reducing the arsenal of therapeutics.

There is a need for better diagnostic tests to accurately predict drug treatment success at an earlier stage, minimising the development of drug resistance. Actiphage® offers the potential for a ‘test of cure’ for TB drug treatment by confirming active TB has been eradicated from the bloodstream.

Test of cure for TB drugs

Actiphage is a phage-based test that may support drug management and the development of new TB drugs. When added to a blood sample, Actiphage finds and penetrates the mycobacteria, overtaking its replication infrastructure to produce more phages and enzymes, which break down the tough cell walls and release the bacterial DNA for analysis with PCR.

Drug resistance was widely discussed on the recent World TB Day and Jane Theaker, CEO of PBD Biotech, developers of Actiphage, says that the in-development diagnostic is attracting interest from drug developers.

“We had anticipated that the main market for Actiphage would be for the screening of those with latent TB infection to find the ‘missing three million’ – the cases of active TB that go undiagnosed and untreated. However, a new opportunity is emerging to monitor the response to treatment.

“The traditional tests, such as IGRA, measure the immune response to infection, which can be heightened even when the patient is recovering. Bacterial DNA circulating in the blood may also be from past infection.

“Actiphage is unique as it uses a phage specific to Mycobacterium tuberculosis which only selects live bacteria that are actively replicating, indicating the disease state of the patient.”

Need for multiple drugs to treat TB

Most commonly used drug regimens for the treatment of drug-sensitive TB requires patients to take multiple drugs for up to six months with routine clinical monitoring. Patients with drug-resistant forms of TB can face longer and more complex treatment journeys, often with significant side effects and treatment costs.

Accurate and rapid drug resistance testing is essential for early diagnosis of both drug-sensitive and drug-resistant TB, but access to testing can be limited due to high costs and technical challenges.

Actiphage has the potential to allow for genotyping of MTB strain.  It releases M.tuberculosis DNA from mycobacteria in a blood sample for downstream amplification and Sanger Sequencing or NGS (Next Generation Sequencing). 

Jane Theaker continues: “Collaborations are vital for the development of pan-TB treatment regimens as treatment requires multiple drugs. With Actiphage there is potential also to identify antimicrobial resistance mutations, which would give doctors insights into which drug combinations to use, increasing the efficacy of these new regimens.”

AACC webinar to discuss phage-based diagnostics

The potential of phage-based diagnostics is to be discussed in a webinar sponsored by PBD Biotech, ‘Phage-Based Laboratory Diagnostics Role in the Detection of Tuberculosis’, hosted by the American Association of Clinical Chemistry (AACC) on 19 April 2023 from 12 – 1 PM (Eastern Time) (5 – 6 PM BST). To participate in the webinar visit aacc.org/education/all-webinars.

Share:

Related posts

Loading...

Join PBD Biotech at the 2023 AACC Clinical Lab Expo, Booth #4578, to learn more about Actiphage

May 26, 2023
Without treatment 1 in 10 people with latent TB will progress to active TB but how can they be identified?

Join PBD Biotech at the 2023 AACC Clinical Lab Expo, Booth #4578, to learn more about Actiphage

May 26, 2023
Without treatment 1 in 10 people with latent TB will progress to active TB but how can they be identified?
pan North West of England’s Health and Life Sciences Cluster fight-against-infectious-disease

Phage-based diagnostics and the fight against infectious disease

May 22, 2023
PBD Biotech to speak at Liverpool School of Tropical Medicine anniversary celebrations
pan North West of England’s Health and Life Sciences Cluster fight-against-infectious-disease

Phage-based diagnostics and the fight against infectious disease

May 22, 2023
PBD Biotech to speak at Liverpool School of Tropical Medicine anniversary celebrations
Actiphage TB diagnostic releases bacterial DNA for qPCR

16 May 2023

New Centre for Phage Research features Actiphage within Innovation Showcase

May 12, 2023
The UK’s first Centre for Phage Research is being officially launched on 16th May and featured in the UK KTN UK Phage Innovation Showcase will be Actiphage®, a phage-based molecular diagnostic for tuberculosis.
Actiphage TB diagnostic releases bacterial DNA for qPCR

16 May 2023

New Centre for Phage Research features Actiphage within Innovation Showcase

May 12, 2023
The UK’s first Centre for Phage Research is being officially launched on 16th May and featured in the UK KTN...
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic tests that are urgently needed to screen LTBI and determine who will progress to active TB disease.
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic...
1 2 … 8 Next »

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!